 Kindred Biosciences, Inc. NASDAQ: KIN, a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2020 and provided updates on its programs. For the first quarter 2020, KindredBio reported net product revenues of 0.6 million and a net loss of 22.8 million, or 0.58 per share, which includes non-recurring charges of 5.1 million. 